Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology
Clinical Trials: Metastatic Melanoma
A listing of clinical trials currently looking for volunteers to enroll in Metastatic Melanoma studies. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
California
San Francisco : California Pacific Medical Center
Clinical Trial of Sutent to Treat Metastatic Melanoma
Illinois
Chicago : Rush Pres St Lukes Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Indiana
Indianapolis : Indiana University Melvin and Bren Simon Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Iowa
Iowa City : University of Iowa Hospitals and Clinics
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Minnesota
Rochester : Mayo Clinic Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Oregon
Portland : Providence Cancer Center
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Pennsylvania
Philadelphia : Fox Chase Cancer Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Tennessee
Nashville : Sarah Cannon Research Institute Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Texas
Dallas :
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Dallas : Mary Crowley Cancer Research Centers - Medical City Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Houston :
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
San Antonio : The START Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
San Antonio : Veterans Affairs at UTHSCSA
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
View More »
San Antonio : Cancer Therapy & Research Center at UTHSCSA
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Virginia
Charlottesville : University of Virginia Health System Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Austria
Graz : Universitätsklinik Graz
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Czech Republic
Brno : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Hradec Kralove : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Praha 2 : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
France
Boulogne-Billancourt : Hôpital Ambroise Paré
DNA Repair Inhibitor & Irradiation on Melanoma
Lille : Centre Oscar Lambret
DNA Repair Inhibitor & Irradiation on Melanoma
Lille : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Marseille : Hôpital de la Timone
DNA Repair Inhibitor & Irradiation on Melanoma
Marseille : Hôpital Sainte Marguerite
Masitinib in Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit
View More »
Nantes : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Paris : Hôpital Saint-Louis
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Institut Curie
DNA Repair Inhibitor & Irradiation on Melanoma
Rennes : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Germany
Berlin : Charité- Universitätsmedizin Berlin
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Berlin : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Essen : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Hannover : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Homburg : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
View More »
Jena : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Kiel : Universitätsklinikum Schleswig-Holstein-Campus Kiel
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Kiel : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Luebeck : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Mainz : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Mannheim : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Nuernberg : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Tuebingen : University Hospital
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Tuebingen : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Italy
Ancona : A.O. UNIVERSITARIA OSPEDALI RIUNITI - OSPEDALE UMBERTO I DI ANCONA - ANCONA (AN) (Italy)
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Genova : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Meldola (FC) : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Milan : European Istitue of Oncology
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Milano : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
View More »
Napoli : Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Napoli : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Pisa : University Hospital Pisa
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Rozzano (MI) : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Siena : Azienda Ospedaliera Universitaria Senese
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Russian Federation
Chelyabinsk : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Moscow : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Pyatigorsk : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
St. Petersburg : GSK Investigational Site Updated
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer
Switzerland
Zürich : Universitäts Spital Zürich
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
